MAT - Janssen
... Patients with Fever: Serum fentanyl concentrations could theoretically increase by approximately one-third for patients with a body temperature of 40°C (104°F) due to temperature-dependent increases in fentanyl release from the system and increased skin permeability. Patients who develop fever shoul ...
... Patients with Fever: Serum fentanyl concentrations could theoretically increase by approximately one-third for patients with a body temperature of 40°C (104°F) due to temperature-dependent increases in fentanyl release from the system and increased skin permeability. Patients who develop fever shoul ...
19 Improving the Oral Absorption of S-SEDDS Formulations
... drug microemulsion with a particle size 150 nm and, preferably, as low as 10–20 nm. By this definition the term SEDDS includes all other self-emulsify formulations that contain a surfactant and a lipid, such as SNEDDS or SMEDDS. The term, SEDDS, based on the above definition includes “self-emulsif ...
... drug microemulsion with a particle size 150 nm and, preferably, as low as 10–20 nm. By this definition the term SEDDS includes all other self-emulsify formulations that contain a surfactant and a lipid, such as SNEDDS or SMEDDS. The term, SEDDS, based on the above definition includes “self-emulsif ...
Effects of single nucleotide polymorphisms and
... OATP1B1 is an influx transporter known to mediate the uptake of various endogenous compounds and xenobiotics. Several sequence variations have been discovered in the SLCO1B1 gene encoding OATP1B1. The aim of this study was to investigate the effects of SLCO1B1 polymorphisms on the pharmacokinetics of ...
... OATP1B1 is an influx transporter known to mediate the uptake of various endogenous compounds and xenobiotics. Several sequence variations have been discovered in the SLCO1B1 gene encoding OATP1B1. The aim of this study was to investigate the effects of SLCO1B1 polymorphisms on the pharmacokinetics of ...
Module III
... The combination tablet is specifically designed to decrease buprenorphine abuse by injection, especially by out of treatment ...
... The combination tablet is specifically designed to decrease buprenorphine abuse by injection, especially by out of treatment ...
Managing Anal Furunculosis in Dogs
... The second goal of therapy should be to reduce the mg/kg PO q48h) was then administered for varying diameter, depth, extent, and recurrence of sinus tracts. durations (8 to 16 weeks). All 27 dogs completed the Medical management comprises immunosuppressive or study, with 33.3% of them showing comple ...
... The second goal of therapy should be to reduce the mg/kg PO q48h) was then administered for varying diameter, depth, extent, and recurrence of sinus tracts. durations (8 to 16 weeks). All 27 dogs completed the Medical management comprises immunosuppressive or study, with 33.3% of them showing comple ...
Methadone Conversion Guideline
... affects more opioid receptors than other opioid analgesics; assistance from palliative care or pain management experts is generally advisable for this transition if patients have been on more than 30 mg for more than a few weeks. Because of its long half-life, methadone is better used as a baseline, ...
... affects more opioid receptors than other opioid analgesics; assistance from palliative care or pain management experts is generally advisable for this transition if patients have been on more than 30 mg for more than a few weeks. Because of its long half-life, methadone is better used as a baseline, ...
Ranitidine Relief
... Ranitidine should therefore be avoided in patients with a history of acute porphyria. Gastric pH: Agents that elevate gastric pH may increase the already present risk of nosocomial pneumonia in intubated ICU patients receiving mechanical ventilation. Impaired renal function: Ranitidine is excreted v ...
... Ranitidine should therefore be avoided in patients with a history of acute porphyria. Gastric pH: Agents that elevate gastric pH may increase the already present risk of nosocomial pneumonia in intubated ICU patients receiving mechanical ventilation. Impaired renal function: Ranitidine is excreted v ...
MDMA powder
... intimate communication with their significant others. In a subsequent publication on the treatment method, the authors reported one patient with severe pain from terminal cancer experienced lasting pain relief and improved quality of life.[15] In the United States, no research on MDMA was allowed at ...
... intimate communication with their significant others. In a subsequent publication on the treatment method, the authors reported one patient with severe pain from terminal cancer experienced lasting pain relief and improved quality of life.[15] In the United States, no research on MDMA was allowed at ...
Public Assessment Report Scientific discussion Tracydal 20 mg, film
... effectiveness of the educational materials. See section IV.5 of this report for further details. The product is indicated for the treatment of severe, treatment-resistant depressive disorder irresponsive to two preceding, adequate standard anti-depressive treatments (including tricyclic antidepressa ...
... effectiveness of the educational materials. See section IV.5 of this report for further details. The product is indicated for the treatment of severe, treatment-resistant depressive disorder irresponsive to two preceding, adequate standard anti-depressive treatments (including tricyclic antidepressa ...
Prescribing Information REYATAZ TM 150 mg REYATAZ TM 200 mg
... of limited clinical experience in patients with preexisting conduction system disease (eg, marked first-degree AV block or second- or third-degree AV block), atazanavir should be used with caution in these patients. [See Clinical Pharmacology (12.2).] Atazanavir in combination with diltiazem increas ...
... of limited clinical experience in patients with preexisting conduction system disease (eg, marked first-degree AV block or second- or third-degree AV block), atazanavir should be used with caution in these patients. [See Clinical Pharmacology (12.2).] Atazanavir in combination with diltiazem increas ...
Cymbalta - GuildLink
... was 38.3% and for duloxetine 60 mg once daily was 19.7% (p=0.004). During the 6month continuation therapy phase of this study, 17.4% of duloxetine-treated patients met the a priori-defined criteria for relapse compared with 28.5% on placebo (p=0.042). Of 88 patients who relapsed during the continuat ...
... was 38.3% and for duloxetine 60 mg once daily was 19.7% (p=0.004). During the 6month continuation therapy phase of this study, 17.4% of duloxetine-treated patients met the a priori-defined criteria for relapse compared with 28.5% on placebo (p=0.042). Of 88 patients who relapsed during the continuat ...
dosimetry in diagnostic radiology for paediatric
... assurance manuals. Monographs and high level educational material, such as graduate texts, are also published in this series. IAEA HUMAN HEALTH REPORTS Human Health Reports complement information published in the IAEA Human Health Series in areas of radiation medicine, dosimetry and medical radiatio ...
... assurance manuals. Monographs and high level educational material, such as graduate texts, are also published in this series. IAEA HUMAN HEALTH REPORTS Human Health Reports complement information published in the IAEA Human Health Series in areas of radiation medicine, dosimetry and medical radiatio ...
MAGNEX Injection
... time should be monitored in these patients, and patients receiving anticoagulant therapy, and exogenous vitamin K administered as indicated. As with other antibiotics, overgrowth of non-susceptible organisms may occur during prolonged use of sulbactam/cefoperazone. Patients should be observed carefu ...
... time should be monitored in these patients, and patients receiving anticoagulant therapy, and exogenous vitamin K administered as indicated. As with other antibiotics, overgrowth of non-susceptible organisms may occur during prolonged use of sulbactam/cefoperazone. Patients should be observed carefu ...
Dasatinib for the treatment of chronic phase chronic myeloid leukemia
... Initially, supported by Phase I and II trial data, dasatinib was recommended at a dose of 70 mg twice-daily for patients with all phases of imatinib-resistant or -intolerant CML or Ph+ ALL. However, considering the reported adverse events of dasatinib at 70 mg twice daily, CA180–034, a randomized, ...
... Initially, supported by Phase I and II trial data, dasatinib was recommended at a dose of 70 mg twice-daily for patients with all phases of imatinib-resistant or -intolerant CML or Ph+ ALL. However, considering the reported adverse events of dasatinib at 70 mg twice daily, CA180–034, a randomized, ...
Serevent - GlaxoSmithKline
... asthma-related death. Data from a large placebo controlled US study that compared the safety of salmeterol (SEREVENT® Inhalation Aerosol) or placebo added to patients usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol (13 deaths out of 13, 176 patients ...
... asthma-related death. Data from a large placebo controlled US study that compared the safety of salmeterol (SEREVENT® Inhalation Aerosol) or placebo added to patients usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol (13 deaths out of 13, 176 patients ...
Phenytoin: A Guide to Therapeutic Drug Monitoring
... How Much Should I Increase the Phenytoin Dose if my Patient is not Responding to Treatment? Guidelines for dosing adjustments based on phenytoin plasma concentrations have been proposed for adults with epilepsy without clinically significant renal or hepatic disease: for plasma phenytoin concentrati ...
... How Much Should I Increase the Phenytoin Dose if my Patient is not Responding to Treatment? Guidelines for dosing adjustments based on phenytoin plasma concentrations have been proposed for adults with epilepsy without clinically significant renal or hepatic disease: for plasma phenytoin concentrati ...
PDF - AIDS Research and Therapy
... combination formulations and does not require laboratory monitoring for toxicity. In 2006, WHO recommended reduced doses of stavudine following the findings of a systematic review that lower doses caused less toxicity without reducing efficacy [1,5]. Most, if not all, of stavudine’s adverse drug rea ...
... combination formulations and does not require laboratory monitoring for toxicity. In 2006, WHO recommended reduced doses of stavudine following the findings of a systematic review that lower doses caused less toxicity without reducing efficacy [1,5]. Most, if not all, of stavudine’s adverse drug rea ...
Inverted-U dopamine D1 receptor actions on prefrontal neurons
... to that in the NPD (left panel) and detuning the population spatial response. High doses of SKF81297 (Fig. 3a, 20–75 nA, bottom panel, n ¼ 12) also suppressed cell firing; however, as these neurons had higher firing rates in the NPD as well, suppression was observed for both the PD and the NPD. In s ...
... to that in the NPD (left panel) and detuning the population spatial response. High doses of SKF81297 (Fig. 3a, 20–75 nA, bottom panel, n ¼ 12) also suppressed cell firing; however, as these neurons had higher firing rates in the NPD as well, suppression was observed for both the PD and the NPD. In s ...
Ritalin LA
... is expected to have minimal effect on the pharmacokinetics of methylphenidate since less than 1% of a radiolabeled dose is excreted in the urine as unchanged compound, and the major metabolite (ritalinic acid), has little or no pharmacologic activity. Hepatic Insufficiency: Ritalin LA has not been s ...
... is expected to have minimal effect on the pharmacokinetics of methylphenidate since less than 1% of a radiolabeled dose is excreted in the urine as unchanged compound, and the major metabolite (ritalinic acid), has little or no pharmacologic activity. Hepatic Insufficiency: Ritalin LA has not been s ...
technical monographs - Nutramax Laboratories
... MSM is a di-methylated sulfone molecule [(CH3)2SO2]. This sulfur-containing organic compound is naturally present in low amounts in fruits, corn, tomatoes, coffee and milk.36 Research supports the inclusion of MSM into a Cosamin formulation as published clinical studies have ...
... MSM is a di-methylated sulfone molecule [(CH3)2SO2]. This sulfur-containing organic compound is naturally present in low amounts in fruits, corn, tomatoes, coffee and milk.36 Research supports the inclusion of MSM into a Cosamin formulation as published clinical studies have ...
Prescribing Information
... have occurred with abacavir, a component of TRIZIVIR (abacavir, lamivudine, and zidovudine). Patients who carry the HLA-B*5701 allele are at a higher risk of a hypersensitivity reaction to abacavir; although, hypersensitivity reactions have occurred in patients who do not carry the HLA-B*5701 allele ...
... have occurred with abacavir, a component of TRIZIVIR (abacavir, lamivudine, and zidovudine). Patients who carry the HLA-B*5701 allele are at a higher risk of a hypersensitivity reaction to abacavir; although, hypersensitivity reactions have occurred in patients who do not carry the HLA-B*5701 allele ...
Ritalin LA - Novartis Pharmaceuticals Corporation
... is expected to have minimal effect on the pharmacokinetics of methylphenidate since less than 1% of a radiolabeled dose is excreted in the urine as unchanged compound, and the major metabolite (ritalinic acid), has little or no pharmacologic activity. Hepatic Insufficiency: Ritalin LA has not been s ...
... is expected to have minimal effect on the pharmacokinetics of methylphenidate since less than 1% of a radiolabeled dose is excreted in the urine as unchanged compound, and the major metabolite (ritalinic acid), has little or no pharmacologic activity. Hepatic Insufficiency: Ritalin LA has not been s ...
Melatonin - Wolverhampton Formulary
... Although behavioural interventions should be the primary intervention and has robust evidence base, exogenous melatonin is the ‘first-line’ medication prescribed for childhood insomnia and sleep disorders. Current guidance and published data around the use of Melatonin is lacking in children. The Ch ...
... Although behavioural interventions should be the primary intervention and has robust evidence base, exogenous melatonin is the ‘first-line’ medication prescribed for childhood insomnia and sleep disorders. Current guidance and published data around the use of Melatonin is lacking in children. The Ch ...
Product Monograph
... adolescents (< 18 years old) to establish dosage recommendations (see ACTION AND CLINICAL PHARMACOLOGY, Special Populations and Conditions - Pediatrics). Therefore, until further data are available, use of linezolid in this age group is not recommended Geriatrics: Of the 2046 patients treated with Z ...
... adolescents (< 18 years old) to establish dosage recommendations (see ACTION AND CLINICAL PHARMACOLOGY, Special Populations and Conditions - Pediatrics). Therefore, until further data are available, use of linezolid in this age group is not recommended Geriatrics: Of the 2046 patients treated with Z ...
Theme of the 3 days` meeting
... similia and whole person principles, and the use of very high dilutions. The effects of high dilutions cannot be explained by a simple molecule-receptor interaction (mechanistic paradigm), the “well established theory” of modern science. Prof. Bastide & Lagache propose an epistemological approach to ...
... similia and whole person principles, and the use of very high dilutions. The effects of high dilutions cannot be explained by a simple molecule-receptor interaction (mechanistic paradigm), the “well established theory” of modern science. Prof. Bastide & Lagache propose an epistemological approach to ...